6 days Ago By Defense World Staff
Renaissance Technologies LLC grew its stake in shares of Ventyx Biosciences, Inc. ( NASDAQ:VTYX – Free Report ) by 99.1% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC).
The institutional investor owned 624,500 shares of the company’s stock after acquiring an additional 310,800 shares during the period. Renaissance Technologies LLC owned 0.88% of Ventyx Biosciences worth $1,368,000 at the end of the most recent reporting period.
A number of other large investors have also recently made changes to their positions in the stock. Catalina Capital Group LLC purchased a new stake in Ventyx Biosciences during the 4th quarter worth about $25,000. AXQ Capital LP bought a new position in shares of Ventyx Biosciences in the fourth quarter valued at approximately $29,000.
Palumbo Wealth Management LLC grew its stake in Ventyx Biosciences by 97.1% during the fourth quarter. Palumbo Wealth Management LLC now owns 23,932 shares of the company’s stock valued at $52,000 after acquiring an additional 11,792 shares in the last quarter.
Wells Fargo & Company MN increased its holdings in Ventyx Biosciences by 23.3% during the 4th quarter. Wells Fargo & Company MN now owns 41,170 shares of the company’s stock worth $90,000 after acquiring an additional 7,768 shares during the period.
Finally, American Century Companies Inc. raised its position in shares of Ventyx Biosciences by 12.4% in the fourth quarter.
American Century Companies Inc. now owns 67,329 shares of the company’s stock worth $147,000 after buying an additional 7,414 shares in the last quarter. 97.
88% of the stock is owned by institutional investors. Analysts Set New Price Targets Separately, HC Wainwright reaffirmed a “neutral” rating on shares of Ventyx Biosciences in a report on Tuesday, January 14th. Ventyx Biosciences Stock Up 3.
3 % NASDAQ VTYX opened at $1.24 on Tuesday. The stock’s 50-day simple moving average is $1.
26 and its two-hundred day simple moving average is $1.86. Ventyx Biosciences, Inc.
has a twelve month low of $0.78 and a twelve month high of $5.66.
The company has a market capitalization of $88.20 million, a price-to-earnings ratio of -0.53 and a beta of 0.
75. Ventyx Biosciences ( NASDAQ:VTYX – Get Free Report ) last announced its quarterly earnings data on Thursday, February 27th. The company reported ($0.
41) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.54) by $0.13.
On average, equities analysts expect that Ventyx Biosciences, Inc. will post -2.09 earnings per share for the current fiscal year.
Ventyx Biosciences Company Profile ( Free Report ) Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company’s lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn’s disease. Further Reading Five stocks we like better than Ventyx Biosciences What Does a Stock Split Mean? Best Defense Stocks in 2025.
.. So Far Election Stocks: How Elections Affect the Stock Market Alphabet Rebounds After Strong Earnings and Buyback Announcement Growth Stocks: What They Are, Examples and How to Invest Could Selling Taiwan Semiconductor Be Buffett’s Biggest Regret? Want to see what other hedge funds are holding VTYX? Visit HoldingsChannel.
com to get the latest 13F filings and insider trades for Ventyx Biosciences, Inc. ( NASDAQ:VTYX – Free Report ). Receive News & Ratings for Ventyx Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ventyx Biosciences and related companies with MarketBeat.
com's FREE daily email newsletter ..
